Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases
AssigneeAstraZeneca AB
InventorsPeter GREASLEY, Christine AHLSTRÖM, Stanko SKRTIC, Robert MENZIES, Anne-Kristina MERCIER, Mikael SUNNÅKER
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.
Claims22
1-9. (canceled)
A method of reducing total body water in a human patient with chronic kidney disease and in need thereof, the method comprising administering to the patient a combination of zibotentan, N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide,
- or a pharmaceutically acceptable salt thereof, and dapagliflozin in amounts effective for reducing total body water in the patient.
A method of reducing risk of fluid retention in a human patient with chronic kidney disease and in need thereof, the method comprising administering to the patient a combination of zibotentan, N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide,
- or a pharmaceutically acceptable salt thereof, and dapagliflozin in amounts effective for reducing total body water in the patient.
A method of reducing the likelihood of cardiovascular death in a human patient with chronic kidney disease and in need thereof, the method comprising administering to the patient, a combination of zibotentan, N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3- sulfonamide,
- or a pharmaceutically acceptable salt thereof, and dapagliflozin in amounts effective for reducing the incidence of cardiovascular or renal death in the patient.
Dependencies are inferred from the claim text.